Diabetes Therapeutic Market Reached $24.9 Billion in 2009
This report provides market estimates and forecasts for the world market for diabetes treatments
Rockville, MD, September 24, 2010 --(PR.com)-- MarketResearch.com has announced the addition of Kalorama Information’s new report “The World Market for Diabetes Treatments” to their collection of reports. For more information, visit:
http://www.marketresearch.com/product/display.asp?productid=2809047
The diabetes market is one of the fastest growing areas within the pharmaceutical sector, one of the few areas that is likely to continue to grow at double digit rates, according to healthcare market research publisher Kalorama Information. The promise of a near-certain market for patients has lead to competition among top names in pharmaceuticals to try to secure a position in the market with a new product, according to “The World Market for Diabetes Treatments.”
Diabetes is typically treated using diet control, exercise, and the monitoring of blood glucose several times a day. In some cases oral medication and/or insulin is prescribed, especially where diet or exercise is not enough, creating an opportunity for drug makers. According to the report, the total diabetes therapeutic market reached $24.9 billion in 2009, increasing 16.4% from the previous year. This level of growth is expected to continue at least for the next two years, according to the Kalorama Information. Major contributing factors to grow are increasing obesity and an aging worldwide population.
“Diabetes is seen as kind of a ‘safe bet’ development area as pharmacos try to carve out a piece of this income stream with a treatment that is a bit more effective,” said Bruce Carlson, Publisher of Kalorama Information. “Unfortunately there has been little or no improvement in the numbers through diet and exercise. Even if there were improvement, there would still be a large pool of existing patients requiring treatment.”
Top companies in the market include NovoNordisk, Sanofi-Aventis, GlaxoSmithKline, Merck and Tekada. Kalorama’s report lists over 100 new diabetes products in the development pipeline by these firms and others. While the entire market is considered safer for investment than other pharmaceutical markets, individual product success is never guaranteed; products will succeed or fail, depending on their effectiveness, marketing, and how well they fit with medical practice.
The report, “The World Market for Diabetes Treatments,” contains more information on epidemiology, products, companies operating in the market, forecasts and market estimates.
http://www.marketresearch.com/product/display.asp?productid=2809047
Contact:
Veronica Franco
MarketResearch.com
vfranco@marketresearch.com
240.747.3016
###
http://www.marketresearch.com/product/display.asp?productid=2809047
The diabetes market is one of the fastest growing areas within the pharmaceutical sector, one of the few areas that is likely to continue to grow at double digit rates, according to healthcare market research publisher Kalorama Information. The promise of a near-certain market for patients has lead to competition among top names in pharmaceuticals to try to secure a position in the market with a new product, according to “The World Market for Diabetes Treatments.”
Diabetes is typically treated using diet control, exercise, and the monitoring of blood glucose several times a day. In some cases oral medication and/or insulin is prescribed, especially where diet or exercise is not enough, creating an opportunity for drug makers. According to the report, the total diabetes therapeutic market reached $24.9 billion in 2009, increasing 16.4% from the previous year. This level of growth is expected to continue at least for the next two years, according to the Kalorama Information. Major contributing factors to grow are increasing obesity and an aging worldwide population.
“Diabetes is seen as kind of a ‘safe bet’ development area as pharmacos try to carve out a piece of this income stream with a treatment that is a bit more effective,” said Bruce Carlson, Publisher of Kalorama Information. “Unfortunately there has been little or no improvement in the numbers through diet and exercise. Even if there were improvement, there would still be a large pool of existing patients requiring treatment.”
Top companies in the market include NovoNordisk, Sanofi-Aventis, GlaxoSmithKline, Merck and Tekada. Kalorama’s report lists over 100 new diabetes products in the development pipeline by these firms and others. While the entire market is considered safer for investment than other pharmaceutical markets, individual product success is never guaranteed; products will succeed or fail, depending on their effectiveness, marketing, and how well they fit with medical practice.
The report, “The World Market for Diabetes Treatments,” contains more information on epidemiology, products, companies operating in the market, forecasts and market estimates.
http://www.marketresearch.com/product/display.asp?productid=2809047
Contact:
Veronica Franco
MarketResearch.com
vfranco@marketresearch.com
240.747.3016
###
Contact
MarketResearch.com
Veronica Franco
240.747.3016
www.marketresearch.com/
Veronica Franco
240.747.3016
www.marketresearch.com/
Contact
Categories